As a result of recent evidence regarding proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors and ezetimibe in some patients, the ACC has released the 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk, which published Sept. 5 in the Journal of the American College of Cardiology .
The 2016 document provided guidance regarding the incorporation of non-statin therapies into treatment strategies to lower low-density lipoprotein (LDL)–cholesterol for patients who may need additional therapies beyond statins.

Source: Click here